TUFM is a potential new prognostic indicator for colorectal carcinoma

Pathology

Volumn 44, Issue 6, 2012, Pages 506-512

  Shi, Hongjun ^a   Hayes, Mark ^a   Kirana, Chandra ^a   Miller, Rosemary ^b   Keating, John ^c   MacArtney Coxson, Donia ^d   Stubbs, Richard ^a  

^a UNIVERSITY OF OTAGO WELLINGTON   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c WELLINGTON HOSPITAL   (New Zealand)

^d INSTITUTE OF ENVIRONMENTAL SCIENCE AND RESEARCH   (New Zealand)

Author keywords

Colorectal carcinoma; Mitochondria; Prognosis; TUFM

Indexed keywords

EID: 84866908800     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e3283559cbe     Document Type: Article

References (53)

1. Ministry of Health New Zealand. Cancer: New Registrations and Deaths 2007. Wellington: Ministry of Health New Zealand, 2010.
2. Jemal A, Siegel R, Xu J,Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
3. Millikan KW, Staren ED, Doolas A. Invasive therapy of metastatic colorectal cancer to the liver. Surg Clin North Am 1997; 77: 27-48.
4. Aschele C, Bergamo F, Lonardi S. Chemotherapy for operable and advanced colorectal cancer. Cancer Treat Rev 2009; 35: 509-16.
5. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004; 96: 1420-5.
6. Chang GJ, Rodriguez-Bigas MA, Skibber JM, Moyer VA. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst 2007; 99: 433-41.
7. Sargent D, Sobrero A, Grothey A, O'Connell MJ, Buyse M, Andre T, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2009; 27: 872-7.
8. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322: 352-8.
9. Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007; 370: 2020-9.
10. Jonker DJ, Spithoff K, Maroun J. Adjuvant systemic chemotherapy for Stage II and III colon cancer after complete resection: an updated practice guideline. Clin Oncol (R Coll Radiol) 2011; 23: 314-22.
11. Benson AB 3rd, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004; 22: 3408-19.
12. O'Connor ES, Greenblatt DY, LoConte NK, et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol 2011; 29: 3381-8.
13. Lin YH, Friederichs J, Black MA, et al. Multiple gene expression classifiers from different array platforms predict poor prognosis of colorectal cancer. Clin Cancer Res 2007; 13: 498-507.
14. Dundas SR, Lawrie LC, Rooney PH, Murray GI. Mortalin is over-expressed by colorectal adenocarcinomas and correlates with poor survival. J Pathol 2005; 205: 74-81.
15. Pei H, Zhu H, Zeng S, et al. Proteome analysis and tissue microarray for profiling protein markers associated with lymph node metastasis in colorectal cancer. J Proteome Res 2007; 6: 2495-501.
16. Ma YL, Peng JY, Zhang P, et al. Heterogeneous nuclear ribonucleoprotein A1 is identified as a potential biomarker for colorectal cancer based on differential proteomics technology. J Proteome Res 2009; 8: 4525-35.
17. Qi Y, Chiu JF, Wang L, Kwong DL, He QY. Comparative proteomic analysis of esophageal squamous cell carcinoma. Proteomics 2005; 5: 2960-71.
18. Li LS, Kim H, Rhee H, et al. Proteomic analysis distinguishes basaloid carcinoma as a distinct subtype of nonsmall cell lung carcinoma. Proteomics 2004; 4: 3394-400.
19. He QY, Cheung YH, Leung SY, Yuen ST, Chu KM, Chiu JF. Diverse proteomic alterations in gastric adenocarcinoma. Proteomics 2004; 4: 3276-87.
20. Spremulli LL, Coursey A, Navratil T, Hunter SE. Initiation and elongation factors in mammalian mitochondrial protein biosynthesis. Prog Nucleic Acid Res Mol Biol 2004; 77: 211-61.
21. Dakubo GD. Mitochondrial Genetics and Cancer. Berlin: Springer-Verlag, 2010.
22. Bellance N, Lestienne P, Rossignol R. Mitochondria: from bioenergetics to the metabolic regulation of carcinogenesis. Front Biosci 2009; 14: 4015-34.
23. Sanchez-Arago M, Chamorro M, Cuezva JM. Selection of cancer cells with repressed mitochondria triggers colon cancer progression. Carcinogenesis 2010; 31: 567-76.
24. Inokuma T, Haraguchi M, Fujita F, Tajima Y, Kanematsu T. Oxidative stress and tumor progression in colorectal cancer. Hepatogastroenterology 2009; 56: 343-7.
25. Dreher D, Junod AF. Role of oxygen free radicals in cancer development. Eur J Cancer 1996; 32A: 30-8.
26. Zhou J, Schmid T, Schnitzer S, Brune B. Tumor hypoxia and cancer progression. Cancer Lett 2006; 237: 10-21.
27. AJCC. AJCC Cancer Staging Handbook. New York: Springer, 2010.
28. Hamilton SR, Aaltonen LA. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System. Lyon: IARC Press, 2000.
29. Lee HS, Kim WH. Tissue array methods for high-throughput clinicopathologic research. Cancer Res Treat 2006; 38: 1-6.
30. Cuezva JM, Ortega AD, Willers I, Sanchez-Cenizo L, Aldea M, Sanchez- Arago M. The tumor suppressor function of mitochondria: translation into the clinics. Biochim Biophys Acta 2009; 1792: 1145-58.
31. Cuezva JM, Krajewska M, de Heredia ML, et al. The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res 2002; 62: 6674-81.
32. Lee HC, Yin PH, Lin JC, et al. Mitochondrial genome instability and mtDNA depletion in human cancers. Ann NY Acad Sci 2005; 1042: 109-22.
33. Lin PC, Lin JK, Yang SH,Wang HS, Li AF, Chang SC. Expression of beta- F1-ATPase and mitochondrial transcription factor A and the change in mitochondrial DNA content in colorectal cancer: clinical data analysis and evidence from an in vitro study. Int J Colorectal Dis 2008; 23: 1223-32.
34. Chang SC, Lin PC, Yang SH, Wang HS, Liang WY, Lin JK. Mitochondrial D-loop mutation is a common event in colorectal cancers with p53 mutations. Int J Colorectal Dis 2009; 24: 623-8.
35. Dang CV, Li F, Lee LA. Could MYC induction of mitochondrial biogenesis be linked to ROS production and genomic instability? Cell Cycle 2005; 4: 1465-6.
36. Echave P, Machado-da-Silva G, Arkell RS, et al. Extracellular growth factors and mitogens cooperate to drive mitochondrial biogenesis. J Cell Sci 2009; 122: 4516-25.
37. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-14.
38. Kim JW, Dang CV. Cancer's molecular sweet tooth and theWarburg effect. Cancer Res 2006; 66: 8927-30.
39. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006; 3: 177-85.
40. Simonnet H, Alazard N, Pfeiffer K, et al. Low mitochondrial respiratory chain content correlates with tumor aggressiveness in renal cell carcinoma. Carcinogenesis 2002; 23: 759-68.
41. Chatterjee A, Mambo E, Sidransky D. Mitochondrial DNA mutations in human cancer. Oncogene 2006; 25: 4663-74.
42. Pollard PJ, Briere JJ, Alam NA, et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet 2005; 14: 2231-9.
43. Formentini L, Martinez-Reyes I, Cuezva JM. The mitochondrial bioenergetic capacity of carcinomas. IUBMB Life 2010; 62: 554-60.
44. Berridge MV, Tan AS. Effects of mitochondrial gene deletion on tumorigenicity of metastatic melanoma: reassessing the Warburg effect. Rejuvenation Res 2010; 13: 139-41.
45. Weinberg F, Hamanaka R, Wheaton WW, et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci USA 2010; 107: 8788-93.
46. Cavalli LR, Varella-Garcia M, Liang BC. Diminished tumorigenic phenotype after depletion of mitochondrial DNA. Cell Growth Differ 1997; 8: 1189-98.
47. van den Bogert C, Dontje BH, Holtrop M, et al. Arrest of the proliferation of renal and prostate carcinomas of human origin by inhibition of mitochondrial protein synthesis. Cancer Res 1986; 46: 3283-9.
48. KudlickiW, Coffman A, Kramer G, Hardesty B. Renaturation of rhodanese by translational elongation factor (EF) Tu. Protein refolding by EF-Tu flexing. J Biol Chem 1997; 272: 32206-10.
49. Caldas TD, El Yaagoubi A, Richarme G. Chaperone properties of bacterial elongation factor EF-Tu. J Biol Chem 1998; 273: 11478-82.
50. Richarme G. Protein-disulfide isomerase activity of elongation factor EF-Tu. Biochem Biophys Res Commun 1998; 252: 156-61.
51. Bhadula SK, Elthon TE, Habben JE, Helentjaris TG, Jiao S, Ristic Z. Heatstress induced synthesis of chloroplast protein synthesis elongation factor (EF-Tu) in a heat-tolerant maize line. Planta 2001; 212: 359-66.
52. Sakai J, Ishikawa H, Kojima S, Satoh H, Yamamoto S, Kanaoka M. Proteomic analysis of rat heart in ischemia and ischemia-reperfusion using fluorescence two-dimensional difference gel electrophoresis. Proteomics 2003; 3: 1318-24.
53. Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005; 10: 86-103.